Readings Newsletter
Become a Readings Member to make your shopping experience even easier.
Sign in or sign up for free!
You’re not far away from qualifying for FREE standard shipping within Australia
You’ve qualified for FREE standard shipping within Australia
The cart is loading…
This issue of Critical Care Clinics, guest edited by Dr. Mitchell M. Levy, focuses on Biomarkers in Critical Care. This is one of four issues each year selected by the series consulting editor, Dr. John Kellum. Articles in this issue include, but are not limited to: The History of Biomarkers; Biomarkers for Identifying Infection; Procalcitonin: Where Are We Now?; Soluble TREM-1: Diagnosis or Prognosis?; Lubricin as a Biomarker in Sepsis; Check Point Inhibitors and Their Role in Immunosuppression in Sepsis; Metabolomics and the Microbiome as Biomarkers in Sepsis; Lactate: Where Are We Now?; Predicting Renal Dysfunction; Biomarkers in the Evolution of ARDS; Biomarkers and RV Dysfunction; Biomarkers and Precision Medicine: State of the Art; The Use of Biomarkers for Population Homogeneity in Clinical Trials; and The Future of Biomarkers.
$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout
This issue of Critical Care Clinics, guest edited by Dr. Mitchell M. Levy, focuses on Biomarkers in Critical Care. This is one of four issues each year selected by the series consulting editor, Dr. John Kellum. Articles in this issue include, but are not limited to: The History of Biomarkers; Biomarkers for Identifying Infection; Procalcitonin: Where Are We Now?; Soluble TREM-1: Diagnosis or Prognosis?; Lubricin as a Biomarker in Sepsis; Check Point Inhibitors and Their Role in Immunosuppression in Sepsis; Metabolomics and the Microbiome as Biomarkers in Sepsis; Lactate: Where Are We Now?; Predicting Renal Dysfunction; Biomarkers in the Evolution of ARDS; Biomarkers and RV Dysfunction; Biomarkers and Precision Medicine: State of the Art; The Use of Biomarkers for Population Homogeneity in Clinical Trials; and The Future of Biomarkers.